Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Humana Inc (HUM) vs Icl Group Ltd (ICL) Price & Performance

Humana IncTrade
Icl Group LtdTrade

Price performance (Past 24H)

Key statistics

Humana Inc vs Icl Group Ltd — how do they compare? Humana Inc trades at $404.19 (market cap $47.81B), while Icl Group Ltd trades at $5.27 (market cap $6.65B). The key difference: Humana Inc is far larger — about 7.2× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.77%). Which is the better fit depends on your goals.

HUMICL
Market Cap
$47.81B$6.65B
Sector
HealthBasic Materials
52-Week High
$409.42$7.03
52-Week Low
$163.67$4.80
Enterprise Value
$56.85B$9.22B
Dividend Yield
0.89%3.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Humana Inc

Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.

The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.

Icl Group Ltd

ICL trades at $5.00, down 0.99% over 24 hours, with a bearish technical signal. The company reported Q1 2026 earnings of $0.11 per share, beating estimates, and recently completed an $800 million senior notes offering. Revenue for 2025 was $7.15 billion with a net income margin of 3.15%, while valuation ratios show a P/E of 24.05 and P/S of 0.88. Analyst consensus is entirely hold-rated, reflecting cautious sentiment amid mixed financial trends.

The outlook for ICL is neutral with modest growth potential, supported by operational improvements and raised 2026 EBITDA guidance. Key risks include elevated raw material costs, foreign exchange headwinds, and competitive pressures in the specialty minerals sector. Investors should weigh stable cash flows against margin compression and debt levels from recent financing activities.

Returns comparison

Trailing returns across standard periods

About Humana Inc

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Read more on HUM

About Icl Group Ltd

ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.

Read more on ICL